Volume 95 Issue 11 | p. 15 | Concentrates
Issue Date: March 13, 2017

Otsuka to acquire Neurovance

Department: Business
Keywords: mergers & acquisitions, ADHD, neuroscience

Otsuka Pharmaceutical will pay $100 million up front and up to $150 million in potential milestone payments to acquire Cambridge, Mass.-based Neurovance, a six-year-old company focused on attention-deficit/hyperactivity disorder. Its lead ADHD candidate is centanafadine, which has completed Phase II clinical trials. According to Neurovance, centanafadine is one of a new generation of triple reuptake inhibitors that modulate the activity of norepinephrine, dopamine, and serotonin. The acquisition will extend Otsuka’s efforts in the area of . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society